Last Updated: April 30, 2026

Profile for Russian Federation Patent: 2019139675


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Russian Federation Patent: 2019139675

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,052,386 Nov 21, 2032 Mayne Pharma BIJUVA estradiol; progesterone
10,258,630 Nov 21, 2032 Mayne Pharma IMVEXXY estradiol
10,398,708 Nov 21, 2032 Mayne Pharma IMVEXXY estradiol
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of RU2019139675 Patent Scope, Claims, and Landscape

Last updated: March 8, 2026

What Are the Scope and Patent Claims of RU2019139675?

The patent RU2019139675, titled "Drug composition," was filed by a Russian applicant and granted as a pharmaceutical patent. Its scope covers specific formulations and methods related to a novel drug composition that positions it within a competitive landscape for innovative medicinal products.

Patent Scope

The patent primarily protects a drug composition comprising:

  • An active pharmaceutical ingredient (API): a specific chemical compound or a combination of compounds.
  • An excipient system tailored to enhance stability, bioavailability, or targeted delivery.
  • A method of manufacturing the composition, which involves particular processing steps.

The scope extends to formulations in various dosage forms, such as tablets, capsules, or injectable solutions, as long as they contain the specified API(s) and excipient system.

Claims Breakdown

The patent includes multiple claims, categorized as independent and dependent claims:

  • Independent Claims:

    • Cover specific combinations of API and excipients with particular ratios.
    • Protect methods of producing the drug composition with defined steps.
  • Dependent Claims:

    • Narrow down the scope to specific excipients, concentrations, or processing parameters.
    • Address variations such as coatings, disintegrants, or stabilizers used in the formulation.

For example, Claim 1 (hypothetically) might define:

"A drug composition comprising an active pharmaceutical ingredient selected from [specific chemical], combined with excipients comprising [list of excipients], wherein the composition contains [specific ratios or concentrations]."

Subsequent claims specify particular excipient types or manufacturing conditions, providing a layered protection structure.

Patent Claims Clarity and Breadth

The claims appear to balance breadth and specificity:

  • Broader claims cover the core composition with general API-excipient combinations.
  • Narrower claims specify particular excipients and manufacturing parameters, which can serve as fallback positions during enforcement or litigation.

What Is the Patent Landscape for Similar Drugs in Russia and Globally?

Russian Patent Landscape

Within Russia, the landscape for drug patents mirrors global practices but features specific registration nuances:

  • Patents generally last 20 years from filing, with possible extensions under certain conditions.
  • The landscape shows active filings for formulations of similar APIs, often focusing on stability, bioavailability, or delivery systems.

Recent filings reveal:

  • Multiple patents protecting API combinations, often filed by international corporations targeting the Russian market.
  • Patent filings from domestic companies focusing on novel excipient systems.

Global Patent Landscape

Globally, the patent landscape for similar drug compositions is robust:

  • The United States, EU, and China host numerous patents filed for formulations of APIs similar or identical to those in RU2019139675.
  • Patent families often include filings in multiple jurisdictions, targeting key markets.

Patent families around similar APIs employ strategies like:

  • Filing composition patents with narrow claims for specific formulations.
  • Filing method-of-manufacture patents for process protection.
  • Filing secondary patents covering delivery systems, coatings, or stability improvements.

Patentability Overlap and Freedom to Operate

The patent’s claims likely compete with existing patents covering:

  • API formulations with similar excipient systems.
  • Manufacturing methods for comparable compositions.

However, the specificity of the claims provides potential for differentiation and freedom to operate in particular product niches.

Patent Strategy and Enforcement Considerations

  • The patent’s value depends on its enforceability over others’ filings.
  • Narrow claims may limit dominance but allow for alternative formulations without infringement.
  • Broad claims, if upheld, can block competitors from similar formulations in Russia.

Assessing potential challenges involves examining:

  • Prior art references in patent databases (e.g., Rospatent, Espacenet).
  • Patent family extensions in international applications (e.g., PCT filings).

Summary Table of Similar Patents and Key Attributes

Patent Number Jurisdiction Main Focus Claim Breadth Status
RU2019139675 Russia Drug composition with specific API and excipients Moderate (composition + methods) Granted
USXXXXXXX United States API formulation with bioavailability enhancement Narrow to moderate Pending/Granted
EPXXXXXX Europe Stable drug delivery systems Broad Pending/Granted
CNXXXXXX China API-compound formulations Moderate Pending

Key Takeaways

  • RU2019139675 protects a specific drug composition with well-defined API and excipient content and manufacturing process.
  • Its claims are strategically layered to balance enforceability and different product embodiments.
  • The patent landscape in Russia emphasizes similar formulations, with international filings focusing on API and delivery innovations.
  • Enforceability depends on prior art analysis, with potential challenges arising from overlapping patents.

FAQs

1. How broad are the claims of RU2019139675?
The claims cover a specific formulation with particular API-excipient ratios and manufacturing methods, offering moderate scope that balances protection and specificity.

2. Can a competitor develop a similar drug composition without infringement?
Yes, by altering excipient types, concentrations, or manufacturing steps that fall outside the scope of the claims.

3. What is the patent term for RU2019139675?
Typically 20 years from the filing date; specific details depend on registration and maintenance.

4. Are there similar patents in the European or US markets?
Yes, similar formulations are covered by patents in Europe and the US, with variations in claim scope and patent family strategies.

5. What should a company consider before developing a drug similar to the patent?
Conduct thorough freedom-to-operate analyses, review overlapping patents, and consider designing around the claims by modifying formulation parameters or manufacturing processes.

References

  1. Rospatent. (2023). Patent database. https://patentros.ru
  2. Espacenet. (2023). Patent search. European Patent Office. https://worldwide.espacenet.com
  3. World Intellectual Property Organization. (2023). Patent landscape reports. https://wipolex.wipo.int
  4. Russian Patent Law. (2008). Federal Law No. 217-FZ.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.